50 results
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
29 May 24
Report of Foreign Private Issuer
7:05am
in vivo studies beneficial outcomes in cardiac ischemia, protection against ischemic/reperfusion injury, reduction in infarct size, improved contractile
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
7 Sep 23
Report of Foreign Private Issuer
7:25am
and triglyceride levels Liver protective effect: protects the liver against Ischemia/Reperfusion injury Rationale for Development Namodenoson for the Treatment
424B4
bup o9auv
12 Feb 20
Prospectus supplement with pricing info
6:46am
F-1/A
nbjf78
3 Feb 20
Registration statement (foreign) (amended)
5:31pm
F-1
au7ska
24 Jan 20
Registration statement (foreign)
4:40pm
F-1/A
EX-10.2
o6cqdk
17 Oct 19
Registration statement (foreign) (amended)
5:29pm
6-K
EX-99.1
gd6ur61sji0lj nz4
6 Sep 19
Report of Foreign Private Issuer
4:18pm
20-F/A
x2xp xfabr9b3wgm40
2 Apr 19
Annual report (foreign) (amended)
6:52am
424B3
lst9a73j
22 Mar 19
Prospectus supplement
4:50pm
F-1/A
iqp 6j0zy7tdizn7
12 Mar 19
Registration statement (foreign) (amended)
4:20pm
F-1
h45h4584abjyn1m9bs
15 Feb 19
Registration statement (foreign)
4:32pm
6-K
EX-99.1
uj2zsl340 b9ukq70
1 Feb 19
Report of Foreign Private Issuer
4:36pm
6-K
EX-99.1
7jrs3b
27 Nov 17
Report of Foreign Private Issuer
12:00am